At the Osaka Center for Adult Diseases, our policy is to provide relatively aggressive treatment for patients with metastatic brain tumours. Our criteria for surgical treatment are reasonable stability of both the primary lesion and any metastases outside the brain and the expectation of a fairly high postoperative quality of life for at least two to three months. When the tumour is larger than a certain size (usually 1 cm) and both improvement in neurological symptoms and prolongation of survival are anticipated, total excision is performed in a single operation. This applies even to multiple brain metastases (up to three) and metastases involving both hemispheres. Sometimes a multiple craniotomy is performed, and the patient's wishes and general condition are given full consideration.
Moreover, an increase in long term survival after tumour excision has been reported by others.5 6 At the Osaka Center for Adult Diseases, our policy is to provide relatively aggressive treatment for patients with metastatic brain tumours. Our criteria for surgical treatment are reasonable stability of both the primary lesion and any metastases outside the brain and the expectation of a fairly high postoperative quality of life for at least two to three months. When the tumour is larger than a certain size (usually 1 cm) and both improvement in neurological symptoms and prolongation of survival are anticipated, total excision is performed in a single operation. This applies even to multiple brain metastases (up to three) and metastases involving both hemispheres. Sometimes a multiple craniotomy is performed, and the patient's wishes and general condition are given full consideration.
The factors affecting the prognosis of patients with metastatic brain tumours have been considered in the medical literature, but these are complex and involve many variables, making it difficult to draw firm conclusions.
We 1978 and 1990, and the study includes follow up data until 18 March 1992. Surgery was performed when prolongation of survival and improvement of the quality of life were expected, and one chemotherapy, radiotherapy, or both without surgery, although the histological diagnosis of small cell carcinoma was sometimes only established after removal of the tumour and such cases were included in our analysis. Chemotherapy and irradiation were given on a case to case basis, as there were no fixed criteria for adjuvant treatment. Whole brain irradiation ranging from 20 Gy (10 irradiation sessions with 2 Gy/day) over two weeks to 50 Gy (20 irradiation sessions with 2-5 Gy/day) over four weeks was performed. Chemotherapy was performed with either carcinostatic agents thought to be effective against the primary lesion or with nitrosourea drugs. In 25 patients, chemotherapy with cisdiaminedichloroplatinum (CDDP) was performed as a specific trial between 1988 and 1990 to evaluate its effectiveness. These data were published elsewhere.7 Briefly, during surgery, 100 mg/sq m of CDDP was given intravenously or intra-arterially. During the first year after surgery, the patients were admitted to hospital every three months, or whenever possible, for intravenous administration of CDDP at the same dose (100 mg/M2). It was given 3-2 times to each patient on average. Radiotherapy was given to 11 randomly selected patients to evaluate the efficacy of chemotherapy alone and of chemotherapy combined with radiotherapy. The preoperative and postoperative functional state (Kamofsky score8) were studied in relation to the survival time. The differences in mean survival time (Kaplan-Meier method) were compared in relation to each of the prognostic factors, and significant differences were determined by the generalised Wilcoxon test and the log rank test. Both tests were applied to between group differences and the log rank test was used for multiple group differences.
Results
The overall mean survival time was 11-6 months (n = 89). Forty eight patients (54%) survived for six months or longer, 37 (42%) for nine months or longer, 21 (24%) for one year or longer, 12 (13%) for 1-5 years or longer, and seven (8%) for two years or longer.
PROGNOSTIC FACTORS AND SURVIVAL TIME Age The patients were divided into those aged 70 years or older at the time of detection of the metastatic brain tumour and those under 70 years of age. No significant difference in the duration of survival was noted between these two groups (fig 1) , and this was also the case when the patients were divided into those aged 65 years or older, and those under 65 (table 2) .
Surgical excision stage and curative nature of the primary lesion A statistically significant difference was confirmed between the patients with and without lung cancer excision ( fig 2) . 4, fig 2) . Although radiotherapy had no significant effect on the mean survival time, chemotherapy significantly prolonged it, and the combination of chemotherapy and radiotherapy was significantly more effective than radiotherapy alone. The mean survival time of patients who received chemotherapy alone was also longer than that of patients who underwent surgery and received no adjuvant therapy (table 4) . For further analysis, the chemotherapy regimens were divided into those involving CDDP, nitrosoureas (ACNU or methyl-CCNU), and other anticancer agents (cyclophosphamide, vincristine, methotrexate, 5-fluorouracil, tegafur, mitomycin-C, and doxorubicin). Nitrosourea agents produced a considerable variation in response and there was a large standard error. Patients given CDDP had a significantly longer mean survival time than patients given other anticancer agents, but there were no other significant differences in terms of the specific agents given (table 5) . Among those receiving chemotherapy alone, four patients in the CDDP group showed Karnofsky scores before and after surgery Thirty two of the 89 patients (36%) had an improved score after surgery, 47 (53%) showed no change, and the score decreased in 10 cases (1 1%). Five patients had a postoperative Karnofsky score of 100% (including one whose preoperative score was 100%) and 43 patients (48%) had a postoperative score of 80%. Of the 56 patients with operative scores below 80%, 13 improved to 80% after surgery (table 6) .
Discussion
There have been numerous reports concerning the factors influencing the prognosis of metastatic brain tumours (table 7) . Our results indicate that the type of tumour (solid or cystic) is a prognostic factor, as there was a trend toward a worse prognosis for cystic tumours. In these patients, multiple brain metastases and subdural tumours tended to develop soon after neurosurgery, suggesting that dissemination of tumour cells occurred through cystic fluid escape during surgery. In this context, CSF cytology also seems to provide important data. Such cytology was not, however, a significant factor in the present study.
Various authors9-"1 have reported that the prognosis worsens with advancing age. This is believed to be due to physical frailty and reduced tolerance of the brain to radiation and chemotherapy. This finding was not supported in our analysis with cut off points of either 65 or 70 years of age. In terms of the histological type of lung cancer, the prognosis is best for adenocarcinoma, followed in descending order by squamous cell carcinoma, large cell carcinoma, and small cell carcinoma (the prognosis is particularly poor for small cell carcinoma). The reported frequency of brain metastases is greatest for large cell carcinoma, followed by small cell carcinoma, adenocarcinoma, and squamous cell carcinoma.'2 In our study, as in others, the outcome for brain metastases from adenocarcinoma was relatively good, whereas that for large cell carcinoma was poor.
The prognosis of patients with lung cancer and brain metastases is usually poor, and the estimated median survival is only one to six months in the presence of an active lesion in the lung. It has been reported that surgical removal of both the brain metastasis and the lung lesion yields a better prognosis.'3 1 ' In the present study, survival was longer when the primary lesion was surgically removed than when it was treated conservatively, regardless of whether its removal preceded or followed excision of the metastatic brain tumour. Although brain metastases may recur even after excision of the primary lesion, it seems that absence of the primary tumour improves the clinical course after removal of the metastases. Zimm et al " and Pladdet et al '6 reported that the prognosis was good when there were no metastases to organs other than the brain, and our findings supported this conclusion. Many other authors have cited the absence of primary and metastatic tumours outside the brain as a favourable prognostic factor.14 1&19 Our data suggest that not only is the prognosis significantly poorer if any extracranial lesions are present, but also that the prognosis is significantly further worsened by the presence of tumour in the lungs, as opposed to other organs.
Many investigators have discussed preoperative functional state as a factor influencing prognosis. I1920 We also found a significant difference between patients with higher and lower Kamofsky scores, particularly those with scores below 40% and above 80%.
Zimm et al, II Yardeni et al,21 and many other authors5 10172022 have reported that the prognosis improves as the interval between the treatment of the primary lesion and the surgical removal of brain metastases becomes longer. This was not confirmed in our present study.
A single brain metastasis, as opposed to multiple lesions, is widely considered to be a favourable prognostic factor, and patients with a solitary brain metastasis are though to be the best candidates for surgery. Few reports are available concerning the surgical treatment of multiple brain metastases, and there have been no previous studies on the prognosis after the excision of such metastases. We found no significant differences in survival after the surgical removal of single metastases (n = 57, mean survival time = 470 days) and multiple (n = 32, mean survival time = 232 days) metastases. Our patients with multiple metastases had been carefully selected by the number and location of the lesions, however, as well as their general condition. The lack of a significant difference between the two groups may also be due to advances in CT and ultrasonic diagnosis, which allow the accurate identification of small tumours, and to advances in surgical techniques that have made it possible to remove small and deeply situated tumours. Furthermore, the survival of a few patients with multiple metastatic brain tumours was possibly prolonged by aggressive chemotherapy or radiotherapy, plus intrathecal chemotherapy when meningeal carcinomatosis developed after tumour removal.
Several investigators have asserted that the prognosis is worse for infratentorial tumours than for supratentorial tumours, due to the inaccessibility of lesions in the posterior cranial fossa or in regions outside the brainstem. 9 192123 When such tumours enlarge and seed the cerebrospinal fluid, metastasis is facilitated and the lesion rapidly becomes inoperable when it extends further into the brainstem.
Our findings showed that there was a trend toward a worse prognosis for cystic tumours than for solid tumours. This may indicate that cystic tumour is a factor in poor prognosis. The current surgical procedure for cystic tumours in our institution is to completely aspirate the cyst fluid in an attempt to prevent tumour dissemination, and then to pack the tumour cavity with cotton to maintain pressure on the cyst wall during its excision, thus reducing the chance that part of the tumour will be left behind. Opinions also differ as to whether it is better to use a carcinostatic agent to which the primary lesion is sensitive, or to use a lipid soluble nitrosourea that can cross the blood brain barrier. As this barrier already seems to be partially disrupted in patients with metastatic brain tumours, it has been reported that drugs that are effective against the primary lesion are also effective against brain metastases.28 29 Therefore, most clinicians advocate the use of carcinostatic agents.30 Surgical specimens sometimes show tumour cell nests in the surrounding brain parenchyma where the bloodbrain barrier is presumably still intact, and we have encountered postoperative tumour recurrence in the surgical cavity. These experiences led us to use nitrosourea agents, but we found that the response to these drugs varied considerably (table 5) .
In summary, the significant prognostic factors were mode of treatment of the lung cancer, histology of 11 and may be credited to aggressive surgery followed by adjuvant treatment.
In summary, this retrospective analysis of 89 surgical cases indicates that improved survival of patients with brain metastases of lung cancer can be achieved by surgical resection of the metastatic lesions followed by appropriate chemotherapy, provided that the primary lung tumour has already been resected.
